NasdaqCM:VCEL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States.


Snowflake Analysis

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Vericel's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VCEL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.8%

VCEL

-0.5%

US Biotechs

2.7%

US Market


1 Year Return

-8.1%

VCEL

26.8%

US Biotechs

9.1%

US Market

Return vs Industry: VCEL underperformed the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: VCEL underperformed the US Market which returned 8.4% over the past year.


Shareholder returns

VCELIndustryMarket
7 Day0.8%-0.5%2.7%
30 Day-0.8%3.6%4.5%
90 Day-6.9%14.2%2.3%
1 Year-8.1%-8.1%28.0%26.8%11.5%9.1%
3 Year375.4%375.4%33.7%29.3%30.6%22.0%
5 Year361.6%361.6%-3.1%-8.9%57.2%39.5%

Price Volatility Vs. Market

How volatile is Vericel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vericel undervalued compared to its fair value and its price relative to the market?

46.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: VCEL ($14.23) is trading below our estimate of fair value ($26.8)

Significantly Below Fair Value: VCEL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VCEL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: VCEL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VCEL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VCEL is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is Vericel forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

58.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VCEL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: VCEL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: VCEL's is expected to become profitable in the next 3 years.

Revenue vs Market: VCEL's revenue (23.6% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: VCEL's revenue (23.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VCEL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Vericel performed over the past 5 years?

17.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VCEL is currently unprofitable.

Growing Profit Margin: VCEL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VCEL is unprofitable, but has reduced losses over the past 5 years at a rate of 17.5% per year.

Accelerating Growth: Unable to compare VCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: VCEL has a negative Return on Equity (-10.44%), as it is currently unprofitable.


Next Steps

Financial Health

How is Vericel's financial position?


Financial Position Analysis

Short Term Liabilities: VCEL's short term assets ($116.5M) exceed its short term liabilities ($18.1M).

Long Term Liabilities: VCEL's short term assets ($116.5M) exceed its long term liabilities ($21.7M).


Debt to Equity History and Analysis

Debt Level: VCEL is debt free.

Reducing Debt: VCEL has no debt compared to 5 years ago when its debt to equity ratio was 0.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VCEL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if VCEL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Vericel's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VCEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VCEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VCEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VCEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VCEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Nick Colangelo (55yo)

7.17yrs

Tenure

US$5,385,527

Compensation

Mr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation. since March 1, 2013 and served as its Treasurer since May 7, 2014. Mr. Colang ...


CEO Compensation Analysis

Compensation vs Market: Nick's total compensation ($USD5.39M) is above average for companies of similar size in the US market ($USD3.17M).

Compensation vs Earnings: Nick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Dominick Colangelo
CEO, President & Director7.17yrsUS$5.39m0.47% $3.0m
Gerard Michel
CFO & VP of Corporate Development5.92yrsUS$2.30m0.56% $3.7m
Michael Halpin
Chief Operating Officer0.92yrUS$1.62m0.0057% $37.2k
Sean Flynn
VP, General Counsel & Corporate Secretary0.50yrno data0.0010% $6.6k
Heidi Hassen
Vice President of Human Resourcesno datano datano data
Jonathan Hopper
Chief Medical Officer1.75yrsno data0.0063% $40.8k
Roland DeAngelis
Senior Vice President of Commercial Operations0.67yrno datano data

1.3yrs

Average Tenure

56.5yo

Average Age

Experienced Management: VCEL's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Dominick Colangelo
CEO, President & Director7.17yrsUS$5.39m0.47% $3.0m
Kevin McLaughlin
Independent Director5.33yrsUS$233.09k0.0039% $25.2k
Paul Wotton
Independent Director5.33yrsUS$218.09k0.0039% $25.2k
Robert Zerbe
Independent Chairman & Lead Director7.58yrsUS$253.09k0.043% $277.4k
Alan Rubino
Independent Director14.67yrsUS$237.59k0.0060% $38.6k
Steven Gilman
Independent Director5.33yrsUS$220.09k0.0039% $25.2k
Joyce Frey-Vasconcells
Member of Scientific Advisory Boardno datano datano data
Mahendra Rao
Member of Scientific Advisory Board10.08yrsno datano data
Karen Hirschi
Member of Scientific Advisory Board10.08yrsno datano data
Heidi Hagen
Independent Director6.75yrsUS$230.09k0.0039% $25.2k

7.2yrs

Average Tenure

61yo

Average Age

Experienced Board: VCEL's board of directors are considered experienced (7.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.


Top Shareholders

Company Information

Vericel Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vericel Corporation
  • Ticker: VCEL
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$648.691m
  • Shares outstanding: 45.11m
  • Website: https://vcel.com

Number of Employees


Location

  • Vericel Corporation
  • 64 Sidney Street
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VCELNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 1997
ATQPDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1997

Biography

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/30 02:02
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.